Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 10/20 | 0.50 |
| ▸ | THRA | P10827 | 9/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523679 | 0.94 | KDM4E (0.49) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6516223 | 0.94 | THRA (0.51) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6513834 | 0.93 | THRB (0.51) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6516461 | 0.93 | THRA (0.50) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6515801 | 0.92 | THRA (0.50) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6512742 | 0.91 | THRB (0.62) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6515562 | 0.88 | MTNR1A (0.50) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6516537 | 0.88 | KDM4E (0.54) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6514103 | 0.88 | KDM4E (0.47) | KDM4ETHRBTHRAMTNR1AKMT2A | |
| SCHEMBL6510936 | 0.87 | KDM4E (0.47) | KDM4ETHRBTHRAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1347959-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
| WO-2002051805-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | KDM4E 1199/4885THRB 1772/4885THRA 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.